TRANSGENE Launches A Rights Issue Of €45.5 Million Euros At A Price Of 10 Euros Per Share
Published: Feb 28, 2014
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Paris:TNG) (Euronext Paris: FR0005175080), a French biopharmaceutical company focused on discovering, developing and manufacturing targeted immunotherapies for the treatment of cancer and infectious diseases, announces today the launch of a rights issue aiming to raise 45.5 million euros.
Help employers find you! Check out all the jobs and post your resume.